PT-141 (Bremelanotide) FDA Approved

What It Is

PT-141 is the development code for bremelanotide, a synthetic cyclic heptapeptide analog of the endogenous neuropeptide α-melanocyte-stimulating hormone (α-MSH). It was developed by Palatin Technologies (originally spun out of the Melanotan program at the University of Arizona), subsequently co-licensed to AMAG Pharmaceuticals for North American rights, and approved by the US FDA on June 21, 2019, under the brand name Vyleesi for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. That approval makes PT-141 one of the very few "research peptides" in the community lexicon that has actually completed the full preclinical-through-Phase-3-through-FDA pipeline to become a legitimate prescription drug.

Structurally, bremelanotide is Ac-Nle-cyclo(Asp-His-D-Phe-Arg-Trp-Lys)-OH — a disulfide-stabilized cyclic sequence whose D-phenylalanine substitution and internal lactam bridge give it resistance to proteolytic degradation and high affinity for the melanocortin-4 receptor (MC4R). This is the key structural departure from its chemical cousin Melanotan II (MT-II), which shares the same core sequence but lacks the 4-position D-Phe substitution that biases selectivity toward MC4R (the sexual-function receptor) and away from MC1R (the skin-pigmentation receptor). That single design change is why PT-141 is a sexual-function drug rather than a tanning drug.

The clinical journey from α-MSH biology to FDA approval spans roughly two decades. Hadley and Dorr's University of Arizona group first showed in the 1960s–80s that α-MSH administered to rats produced spontaneous erections. That observation — initially an incidental finding in a melanocortin research program aimed at photoprotection — became the pharmacological starting point for both Melanotan II and bremelanotide. Early bremelanotide development pursued intranasal dosing for erectile dysfunction in men, which was abandoned after blood pressure signals in Phase 2 at the doses required for an ED effect. Subsequent clinical development pivoted to subcutaneous on-demand dosing in premenopausal women with HSDD. The two identical RECONNECT Phase 3 trials (pooled N=1,247) demonstrated statistically significant improvement in sexual desire and related distress, forming the basis of FDA approval.

Outside of the FDA-approved indication, PT-141 has a substantial off-label following in the optimization community for situational use in both men and women. Male on-demand ED use — particularly among men who are non-responders to PDE5 inhibitors — is the most common off-label context. Because PT-141 acts centrally (CNS-mediated) rather than peripherally (vascular, like sildenafil/tadalafil), its mechanism complements rather than overlaps with the PDE5 class, and the two are sometimes combined — though that combination has not been systematically studied in a registrational trial.

Mechanism of Action

PT-141 is a centrally-acting drug. Unlike PDE5 inhibitors (sildenafil, tadalafil), which act peripherally on smooth muscle in the corpus cavernosum to enhance an existing erection-permissive state, bremelanotide acts in the brain to initiate arousal and desire. That mechanistic difference is the organizing fact around which every other feature of its clinical profile is organized.

• MC4R agonism (primary mechanism) — Bremelanotide binds and activates melanocortin-4 receptors expressed in the paraventricular nucleus of the hypothalamus, medial preoptic area, and limbic regions. MC4R activation in these circuits drives sexual motivation, arousal, and pro-erectile output via descending autonomic pathways.
• MC3R agonism (secondary) — Bremelanotide also binds MC3R with high affinity. MC3R activation contributes to the overall pharmacological profile, particularly in reward-related and homeostatic circuits, but plays a secondary role to MC4R in the sexual-function phenotype.
• Relative MC1R sparing — Compared to Melanotan II, bremelanotide has reduced MC1R activity. This is why PT-141 produces minimal skin darkening at therapeutic doses, while MT-II produces pronounced tanning. Pigmentation signals still exist (focal hyperpigmentation is listed in the Vyleesi label) but are far less prominent.
• Downstream dopaminergic activation — MC4R activation in the medial preoptic area of the hypothalamus increases dopaminergic tone in the mesolimbic pathway. This dopaminergic signal is the proximal neurochemical event most closely tied to the subjective "desire" experience, and dopamine antagonism blunts PT-141's pro-sexual effect in animal models.
• Oxytocin-adjacent signaling — Some preclinical work suggests MC4R-expressing neurons in the paraventricular nucleus co-release or trigger downstream oxytocinergic signaling, which may contribute to the affiliative and emotional components of the PT-141 experience reported by some users.
• Pharmacokinetics-pharmacodynamics mismatch — Plasma half-life is approximately 2 hours, yet behavioral effects on sexual function persist for 4–8 hours. This discrepancy reflects receptor residence time, slow CNS washout, and downstream neurochemical cascades that outlast the parent drug.
• Blood pressure effect — MC4R activation transiently increases sympathetic outflow, producing a modest rise in systolic blood pressure (~6 mmHg peak) and a reflex decrease in heart rate (~5 bpm). This effect is time-limited to the first 2–6 hours after dosing and is the basis for the uncontrolled-hypertension contraindication in the Vyleesi label.
• Non-testosterone-dependent — Unlike strategies that work through androgen replacement, PT-141's effect does not require baseline testosterone elevation. This makes it a plausible option for premenopausal women (in whom testosterone therapy for HSDD is off-label) and for men with ED despite normal testosterone.

What the Research Shows

Across the clinical development program, Palatin reports approximately 3,500 subjects across 43 completed studies, making bremelanotide one of the most extensively human-studied peptides in the optimization lexicon.

• α-MSH mechanistic origin (Hadley group, 1980s) — Early rodent observations that α-MSH and the linear "super-potent" analog [Nle⁴, D-Phe⁷]-α-MSH (Melanotan II, MT-II) produced pro-erectile and pro-arousal effects independent of visual or tactile stimuli established the melanocortin-system-as-sexual-function target hypothesis that PT-141 ultimately exploited.
• PT-141 proof of concept (Molinoff et al., 2003; PMID 12851303) — Initial human pharmacology characterization of PT-141 as a centrally-acting melanocortin agonist suitable for clinical development in sexual dysfunction.
• Male ED Phase 2 (Rosen, Diamond et al., Int J Impot Res 2004; PMID 14999221) — Subcutaneous PT-141 at 0.3–10 mg in healthy men and sildenafil-non-responder ED patients. Statistically significant erectile response at doses >1 mg, well-tolerated up to 10 mg in healthy men and up to 6 mg in ED patients.
• Intranasal ED trials (2006–2008) — Program pursued intranasal PT-141 for situational ED but was discontinued due to transient blood pressure elevation at the doses required for consistent ED efficacy. This forced the subsequent clinical pivot to SubQ on-demand dosing.
• Sildenafil-salvage Phase 2 (Rosen, Diamond et al., J Urol 2008) — Intranasal bremelanotide + sildenafil vs placebo + sildenafil in men with sildenafil-refractory ED. Combination was superior to sildenafil alone on erectile outcomes — the proof-of-principle for centrally-acting + peripherally-acting combination.
• HSDD Phase 2b dose-ranging (Clayton et al., 2016) — Selected 1.75 mg SubQ as the dose for Phase 3 after showing efficacy on sexual desire and distress with acceptable tolerability.
• RECONNECT Phase 3 (Kingsberg et al., Obstet Gynecol 2019; PMID 31599840) — Two identical trials in premenopausal women with acquired, generalized HSDD. Subcutaneous 1.75 mg as needed, with frequency limited to ≤8 doses/month. Both trials demonstrated statistically significant increases in sexual desire (FSFI-desire subscale) and statistically significant reductions in distress (FSDS-DAO item 13) vs placebo. This was the registrational basis for FDA approval.
• RECONNECT exit study (Kingsberg et al., 2021; PMID 33538638) — Qualitative patient-experience assessment showing meaningful subjective improvement in intimate relationship quality and self-reported satisfaction among responders.
• Integrated safety (Clayton et al., J Womens Health 2022; PMID 35147466) — Pooled safety across the clinical development program. Most common AEs: nausea (40% vs 1.3% placebo), flushing (20.3% vs 1.3%), headache (11.3% vs 1.9%), injection site reactions (5.4% vs 0.5%). Most AEs mild-to-moderate; no deaths. Cardiovascular caution, blood pressure control required.
• Prespecified RECONNECT subgroup analyses (Simon et al., 2022; PMID 35230162) — Efficacy generally consistent across age, relationship status, prior HSDD duration, and comorbid conditions.

Human Data

Bremelanotide has one of the largest human-study databases of any peptide in the optimization space. A summary of the major human datasets:

• Phase 1 pharmacokinetics/safety — Healthy men and women across multiple single-ascending and multiple-ascending dose studies. SubQ, IV, and intranasal routes characterized. PK profile: ~2 hour plasma half-life, dose-proportional exposure.
• Male ED Phase 2 (Rosen et al., 2004; PMID 14999221) — Subcutaneous PT-141 0.3–10 mg produced erectile response at doses >1 mg in healthy men and in sildenafil-non-responders.
• Intranasal ED Phase 2 (2006–2008) — Program terminated due to dose-dependent blood-pressure signal at efficacious doses.
• Sildenafil-salvage Phase 2 (Diamond et al., J Urol 2007; Rosen et al., 2008) — Intranasal bremelanotide added to sildenafil in PDE5-refractory ED produced additive erectile benefit over sildenafil alone.
• HSDD Phase 2b dose-ranging (Clayton et al., Womens Health (Lond) 2016) — Established 1.75 mg SubQ as the Phase 3 dose.
• RECONNECT Phase 3 — Study 301 (NCT02338960) — ~640 premenopausal HSDD patients; co-primary endpoints: change in FSFI-desire domain and FSDS-DAO item 13. Both met statistical significance.
• RECONNECT Phase 3 — Study 302 (NCT02333071) — Identical design replicate. Both endpoints met.
• RECONNECT open-label extension (Simon et al., 2019) — 52-week open-label extension demonstrated sustained treatment effect and consistent safety.
• Integrated safety database (N ≈ 3,500; Clayton 2022) — Across the development program, safety findings consistent with Phase 3.
• FDA approval — June 21, 2019. Brand name Vyleesi. Commercialized by Palatin Technologies. Label restricts to premenopausal women, on-demand use, max 8 doses/month, with explicit cardiovascular and blood-pressure cautions.

Outside the labeled indication, evidence for male ED, postmenopausal women, and situational off-label use is supported by earlier-phase studies, large case series, and practitioner reports but not by registrational trials. That evidence gap is why the Vyleesi label is narrow even though off-label community use is broad.

Dosing from the Literature

The FDA-approved dose and schedule come directly from the RECONNECT Phase 3 protocol. Off-label community dosing patterns derive from the Phase 2 male ED program and practitioner reports.

Reconstitution & Storage

Vyleesi is supplied as a sterile pre-filled autoinjector (1.75 mg bremelanotide in 0.3 mL). Research vials of bremelanotide (for off-label or international compounding) are typically supplied as 10 mg lyophilized powder.

• Reconstitution — Inject BAC water down the inside vial wall at 45°, swirl gently, never shake. Solution is clear and colorless; slight yellow tint acceptable.
• Storage — Unreconstituted powder: refrigerate; room temp acceptable short-term. Reconstituted: 2–8°C, use within 28–30 days. Do not freeze reconstituted peptide.
• Injection site — Abdomen (at least 2 inches from navel) or anterolateral thigh. Rotate sites.
• Timing — Peak effect ~45 min to 2 hr post-injection; subjective effect often persists 4–8 hr.
• Inspection — Discard if cloudy, discolored, or particulates.

→ Use the Kalios Peptide Calculator for exact syringe units

Side Effects & Risks

The Vyleesi label provides the gold-standard AE profile because it reflects pooled Phase 3 data (N=1,247):

• Nausea (~40% on first dose) — Dominant adverse effect. Tends to be most intense on the first dose, typically moderates with subsequent use. Ondansetron or ginger 30 min pre-dose is commonly reported to help; the label does not formally recommend prophylaxis but it is common clinical practice.
• Flushing (~20%) — Facial warmth and redness, typically within the first hour.
• Headache (~11%) — Usually mild-to-moderate.
• Injection site reactions (~5%) — Local erythema, pain, pruritus.
• Blood pressure elevation — Transient ~6 mmHg systolic increase, peak 2–4 hr post-dose, resolved by 12 hr. Uncontrolled hypertension is a Vyleesi contraindication. Anyone with BP >140/90 or uncontrolled cardiovascular disease should not use.
• Focal hyperpigmentation (<3%) — Particularly in darker-skinned individuals or with repeated dosing. Usually localized to face, gums, or breasts. Unlike Melanotan II, systemic tanning is uncommon at 1.75 mg.
• Cardiovascular cautions — Not for patients with uncontrolled hypertension or clinically significant cardiovascular disease. Drug-drug interactions with medications that slow gastric emptying can reduce oral drug absorption of concurrent medications.
• Alcohol interaction — Theoretical additive BP effect; label warns about concurrent alcohol. Anecdotally, moderate alcohol does not appear to cause dramatic interaction, but acute heavy use + bremelanotide is inadvisable.
• Pregnancy — Category not established; avoid in pregnancy and during attempted conception.
• Melanoma / pigmentation concerns — Unlike MT-II, PT-141's relative MC1R sparing means systemic melanogenic drive is far less prominent. Nonetheless, users with a history of melanoma, numerous atypical nevi, or strong melanoma family history should exercise caution and maintain dermatologic screening.
• Contraindications — Uncontrolled hypertension, cardiovascular disease, pregnancy.

Bloodwork & Monitoring

Because PT-141 is approved and clinically familiar, monitoring guidance is relatively well-defined:

• Blood pressure — Document baseline systolic/diastolic. Target <140/90 before initiation. Recheck if any cardiovascular symptoms or new antihypertensive changes.
• Resting heart rate — Baseline and during first several doses if cardiovascular concern.
• Skin / dermatologic screen — Baseline skin check in users with heavy nevi or melanoma history; repeat annually.
• Liver function — Not routinely required by the Vyleesi label; reasonable to document baseline if chronic off-label use anticipated.
• Hormonal context — For premenopausal HSDD, baseline FSH, estradiol, prolactin, and TSH are reasonable to rule out other causes of low desire before prescribing.
• Cardiovascular history review — The label explicitly excludes uncontrolled CVD; clinical intake should address MI, stroke, arrhythmia, and antihypertensive regimen.
• Subjective response tracking — FSFI-desire subscale and FSDS-DAO item 13 are the validated patient-reported instruments used in Phase 3 and are reasonable for outcome tracking.

What to Expect — Timeline

Individual response varies. The following synthesizes Phase 3 trial data and off-label user reports.

• Pre-dose (30–45 min) — Inject SubQ. A pre-dose anti-nausea (ondansetron or ginger) is worth considering for first several doses.
• 0–30 min — Mild flushing, facial warmth. Nausea onset for some users. Subtle shift in subjective arousal — often described as "cognitively alert to sexual stimuli" rather than "immediately turned on."
• 30–90 min — Peak subjective effect window. Responders describe increased baseline desire, reduced anxious overthinking, increased reactivity to sexual cues, and (in men) easier achievement of erection. Nausea peaks and begins to subside.
• 1.5–4 hr — Plateau. Most of the sexual activity window for on-demand use. BP rise is in its maximum range here; flushing often present.
• 4–8 hr — Gradual tailing of effect. Subjective arousal persists longer than plasma PK would predict (receptor residence time + downstream cascade).
• 8–12 hr — Effect largely resolved; BP back to baseline; flushing gone. Some users report mild subjective "afterglow" or improved mood-affect for 12–24 hr.
• First-dose vs subsequent-dose — Nausea is most intense on the first 1–3 doses and typically moderates with subsequent exposures. Efficacy does not appear tachyphylactic over the 8-dose/month cap.
• Non-responders — A subset of users describe no perceptible effect at 1.75 mg. Higher-dose attempts generally increase side effects without proportionally increasing benefit. If no subjective response in 2–3 trials with adequate timing, PT-141 is likely a non-match and further escalation is not productive.
• If you feel worse — Severe headache, chest pain, sustained hypertension, vision changes — stop and evaluate. PT-141 is an on-demand drug; chronic daily use is not the intended pattern and amplifies risk without adding benefit.

Practical User Notes

• Test dose before real use — The nausea response varies enormously. Do a trial 0.5–1 mg dose in a non-intimate context to establish personal tolerance before dosing for an actual occasion.
• Pre-dose anti-nausea is the single biggest quality-of-life lever — Ondansetron 4–8 mg or ginger extract 30–45 min pre-dose reliably blunts the dominant side effect. This is practitioner standard despite not being formally labeled.
• Timing matters — 45 min before anticipated activity is the label recommendation. Too early → peak effect dissipates. Too late → onset has not started.
• Dose size is not linear — 1.75 mg is the Phase 3 dose for women. Men often use 1.0–2.0 mg. Going to 3–4 mg increases nausea and BP dramatically without proportional benefit.
• Avoid on the same day as heavy alcohol — Additive BP / flushing effect and impaired judgement about side effects.
• If nausea is severe on first dose, halve the dose for next time — Personal sensitivity varies; 0.75–1.0 mg with anti-nausea is often the sweet spot for nausea-sensitive users.
• Skin screening — Users with a melanoma history, significant atypical nevi, or heavy sun damage should have a dermatologic baseline before chronic off-label use.
• Injection technique — 29G–31G insulin syringe, SubQ in abdomen or thigh, at 45°. Rotate sites.
• Dosing frequency — Label: max 8 doses/month. Exceeding this does not improve outcomes and compounds cardiovascular risk.
• Combination with PDE5 (men) — Off-label. If attempting, use lower doses of both (e.g. 1.0 mg PT-141 + 25 mg sildenafil) rather than standard doses of both, to avoid stacked BP effects.
• Storage discipline — Reconstituted solution in refrigerator, 28–30 days max. Keep out of direct light. Warm to room temp before injection.
• Red flags to stop — Severe headache, vision changes, chest pain, sustained BP >160/100, new skin pigmentation that persists, any syncope. Cessation first, clinical evaluation second.

Commonly Stacked With

→ Check compound compatibility in the Stack Builder

Regulatory Status

Related Compounds

People researching PT-141 often also look at these:

Next Steps

Key References

1. Kingsberg SA, Clayton AH, Portman D, Williams LA, Krop J, Jordan R, Lucas J, Simon JA. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstet Gynecol. 2019;134(5):899-908. PMID: 31599840. DOI: 10.1097/AOG.0000000000003500.
2. Dhillon S, Keam SJ. Bremelanotide: First Approval. Drugs. 2019;79(14):1599-1606. PMID: 31429064. DOI: 10.1007/s40265-019-01187-w.
3. Clayton AH, Kingsberg SA, Portman D, Sadiq A, Krop J, Jordan R, Lucas J, Simon JA. Safety Profile of Bremelanotide Across the Clinical Development Program. J Womens Health (Larchmt). 2022;31(2):171-182. PMID: 35147466.
4. Rosen RC, Diamond LE, Earle DC, Shadiack AM, Molinoff PB. Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra. Int J Impot Res. 2004;16(2):135-142. PMID: 14999221.
5. Molinoff PB, Shadiack AM, Earle D, Diamond LE, Quon CY. PT-141: a melanocortin agonist for the treatment of sexual dysfunction. Ann N Y Acad Sci. 2003;994:96-102. PMID: 12851303.
6. Simon JA, Kingsberg SA, Portman D, Williams LA, Krop J, Jordan R, Lucas J, Clayton AH. Long-term safety and efficacy of bremelanotide for hypoactive sexual desire disorder. Obstet Gynecol. 2019;134(5):909-917. PMID: 31599841.
7. Kingsberg SA, Clayton AH, Portman D, et al. The Patient Experience of Premenopausal Women Treated with Bremelanotide for Hypoactive Sexual Desire Disorder: RECONNECT Exit Study Results. J Womens Health (Larchmt). 2021. PMID: 33538638.
8. Simon JA, Kingsberg SA, Portman D, et al. Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide. J Sex Med. 2022. PMID: 35230162.
9. Clayton AH, Althof SE, Kingsberg S, DeRogatis LR, Kroll R, Goldstein I, Kaminetsky J, Spana C, Lucas J, Jordan R, Portman DJ. Bremelanotide for female sexual dysfunctions in premenopausal women: A randomized, placebo-controlled dose-finding trial. Womens Health (Lond). 2016;12(3):325-337.
10. Diamond LE, Earle DC, Heiman JR, Rosen RC, Perelman MA, Harning R. An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist. J Sex Med. 2006;3(4):628-638. PMID: 16839319.
11. Rosen RC, Diamond LE, Earle DC, Shadiack AM. Salvage of Sildenafil Failures With Bremelanotide: A Randomized, Double-Blind, Placebo Controlled Study. J Urol. 2008;179(3):1060-1066.
12. Molinoff PB, Shadiack AM, Hadley ME. Melanocortin-4 receptor agonists and erectile dysfunction. Endocrine. 2006;30(1):39-48.
13. Hadley ME, Dorr RT. Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization. Peptides. 2006;27(4):921-930. PMID: 16406139.
14. US Food and Drug Administration. VYLEESI (bremelanotide injection) prescribing information. 2019. Reference ID: 4436693.
15. Pfaus JG, Shadiack A, Van Soest T, Tse M, Molinoff P. Selective facilitation of sexual solicitation in the female rat by a melanocortin receptor agonist. Proc Natl Acad Sci U S A. 2004;101(27):10201-10204. PMID: 15226502.
16. ClinicalTrials.gov. Study to Evaluate the Efficacy and Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (RECONNECT 301). NCT02338960.
17. ClinicalTrials.gov. Study to Evaluate the Efficacy and Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (RECONNECT 302). NCT02333071.
18. King SH, Mayorov AV, Balse-Srinivasan P, Hruby VJ, Vanderah TW, Wessells H. Melanocortin receptors, melanotropic peptides and penile erection. Curr Top Med Chem. 2007;7(11):1098-1106. PMID: 17584130.
19. Kingsberg SA, Althof S, Simon JA, et al. Female Sexual Dysfunction—Medical and Psychological Treatments, Committee 14. J Sex Med. 2017;14(12):1463-1491. PMID: 29198504.
20. Bremelanotide. In: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2021. Bookshelf ID NBK573221.